Table 1.
Patient demographics
| Patient ID/cohort | Dose (VP) | Dx | Age | Sex | KPS | # prior CTx | Mets (# of sites) | # of doses | ++Disease Status after tx | Survival (Months) |
|---|---|---|---|---|---|---|---|---|---|---|
| 002/1 | 109 | C | 67 | M | 70 | >3 | 4 | 3 | PD | 3 (−) |
| 003/1 | 109 | R | 63 | M | 100 | 5 | 2 | 3 | PD | 9 (−) |
| 004/1 | 109 | C | 53 | F | 100 | 2 | 3 | 3 | PD | 11 (−) |
| 005/2^ | 1010 | C | 60 | M | 100 | 3 | 3 | 3 | SD | 12 (+) |
| 007/2 | 1010 | C | 52 | M | 80 | 2 | 5 | 1 | PD | 1 (−) |
| 008/2 | 1010 | C | 42 | F | 100 | 3 | 3 | 3 | PD | 12 (+) |
| 010/2 | 1010 | C | 58 | M | 90 | 3 | 3 | 3 | PD | 12 (−) |
| 011/3 | 1011 | R | 50 | M | 100 | 5 | 1 | 3 | PD | 12 (+) |
| 012/3 | 1011 | C | 48 | M | 100 | 1 | 2 | 3 | PD | 12 (+) |
| 013/3 | 1011 | R | 62 | M | 100 | 3 | 2 | 3 | PD | 4 (−) |
| 500/3 | 1011 | C | 55 | M | 80 | 4 | 3 | 3 | PD | 12 (+) |
| 015/3 | 1011 | C | 58 | F | 80 | 3 | 4 | 3 | PD | 10 (−) |
| 016/3@ | 1011 | C | 53 | F | 100 | 3 | 4 | 3 | PD | 6 (−) |
| 017/3* | 1011 | R | 52 | F | 90 | 3 | 2 | 3 | PD | 3 (−) |
| 501/II | 1011 | R | 54 | M | 90 | 1 | 1 | 3 | PD | 12 (+) |
| 502/II | 1011 | C | 66 | F | 80 | 1 | 2 | 2 | PD | 3 (−) |
| 019/II | 1011 | C | 69 | M | 90 | 1 | 3 | 3 | PD | 12 (+) |
| 020/II^ | 1011 | C | 59 | M | 100 | 5 | 4 | 3 | SD | 12 (+) |
| 021/II^ | 1011 | C | 51 | F | 100 | 4 | 3 | 3 | PD | 12 (+) |
| 506/II | 1011 | C | 77 | F | 80 | 2 | 2 | 3 | PD | 3 (−) |
| 023/II | 1011 | C | 51 | F | 100 | 3 | 4 | 3 | PD | 4 (−) |
| 504/II | 1011 | C | 57 | M | 90 | 3 | 3 | 3 | PD | 12 (+) |
| 507/II | 1011 | R | 58 | M | 90 | 2 | 2 | 3 | PD | 12 (+) |
| 024/II | 1011 | C | 67 | M | 90 | 2 | 3 | 3 | PD | 12 (+) |
| 025/II | 1011 | C | 62 | F | 100 | 2 | 4 | 3 | PD | 7 (−) |
| 026/II | 1011 | C | 53 | M | 100 | 3 | 2 | 2 | PD | 4 (−) |
| 030/5 | 5 × 1011 | C | 38 | M | 90 | 4 | 3 | 3 | PD | 10 (+) |
| 031/5 | 5 × 1011 | R | 72 | F | 90 | 4 | 2 | 3 | SD | 9 (+) |
| 032/5@ | 5 × 1011 | R | 53 | M | 90 | 4 | 3 | 3 | PD | 6 (−) |
| 033/5 | 5 × 1011 | R | 48 | F | 90 | >3 | 2 | 3 | PD | 5 (−) |
| 034/5 | 5 × 1011 | C | 62 | M | 100 | 5 | 4 | 3 | PD | 7 (+) |
| 035/5 | 5 × 1011 | C | 60 | F | 90 | 3 | 5 | 2 | PD | 2 (−) |
Dx diagnosis, C colon, R rectal cancer, KPS Karnofsky performance status, PD progressive disease, SD stable disease
* concurrent cetuximab; ^concurrent bevacizumab; @ concurrent panitumumab
++Represents disease status at 9 weeks post-initiation of immunizations
(+) Alive; (−) Dead at last follow-up